验证数据展示
经过测试的应用
Positive IF/ICC detected in | HeLa cells |
推荐稀释比
应用 | 推荐稀释比 |
---|---|
Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
产品信息
CL594-66310 targets TRAF3 in IF/ICC applications and shows reactivity with human, mouse samples.
经测试应用 | IF/ICC Application Description |
经测试反应性 | human, mouse |
免疫原 | TRAF3 fusion protein Ag12185 种属同源性预测 |
宿主/亚型 | Mouse / IgG2a |
抗体类别 | Monoclonal |
产品类型 | Antibody |
全称 | TNF receptor-associated factor 3 |
别名 | CAP 1, CAP1, CD40 binding protein, CD40bp, CRAF1, LAP1, LMP1 associated protein 1, TRAF3 |
计算分子量 | 568 aa, 64 kDa |
GenBank蛋白编号 | BC075087 |
基因名称 | TRAF3 |
Gene ID (NCBI) | 7187 |
RRID | AB_2919976 |
偶联类型 | CoraLite®594 Fluorescent Dye |
最大激发/发射波长 | 588 nm / 604 nm |
形式 | Liquid |
纯化方式 | Protein A purification |
UNIPROT ID | Q13114 |
储存缓冲液 | PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA , pH 7.3 |
储存条件 | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
TNF receptor-associated factor 3 (TRAF3) has many alternative names including CAP-1, CD40 receptor-associated factor 1(CRAF1), CD40-binding protein(CD40BP) and LMP1-associated protein 1 (LAP1). TRAF3 regulates pathways leading to the activation of NF-kappa-B and MAP kinases, and plays a central role in the regulation of innate immune response. It modulates signaling pathways leading to the production of cytokines and interferon. As an essential constituent of several E3 ubiquitin-protein ligase complexes, TRAF3 promote 'Lys-63'-linked ubiquitination of target proteins. Moreover, TRAF3 undergoes both 'Lys-48'-linked and 'Lys-63'-linked ubiquitination in response to various stimuli and is deubiquitinated by OTUB1, OTUB2 and OTUD5.
实验方案
Product Specific Protocols | |
---|---|
IF protocol for CL594 TRAF3 antibody CL594-66310 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |